ALTSTATION.IO

Stryker Corporation (SYK) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$355.03

Change

-2.04%

Market Cap

$135.77B

Avg Volume

1.8M

Company Overview

Stryker Corporation, headquartered in Portage, Michigan, is a leading player in the medical technology field. The company offers a wide range of products through two main divisions: MedSurg and Neurotechnology, and Orthopaedics. Their offerings include surgical equipment, navigation systems, minimally invasive devices for stroke treatment, and implants for joint replacements. Their products are sold to hospitals, doctors, and healthcare facilities globally, reaching around 75 countries.

Stryker is a market leader in the medical devices sector, known for its strong brand and comprehensive product portfolio. Key competitors include Medtronic and Johnson & Johnson, which pose significant challenges. Stryker maintains its edge through continuous innovation and a robust sales network. However, rising costs and regulatory pressures could threaten its margins in the long run.

Currently, Stryker is positioned for growth, with recent investments in technology and acquisitions aimed at expanding its product offerings. The company has been focusing on integrating digital solutions, including AI for virtual care, to enhance operational efficiency and patient outcomes. Their financial performance shows resilience, with a steady revenue increase, suggesting they are on a positive trajectory despite market headwinds.

Key Financials

Market Cap

$135.77B

Revenue

$25.12B

EBITDA

$6.95B

Gross Margin

65.0%

Profit Margin

12.9%

Revenue Growth

11.4%

Total Cash

$4.10B

Total Debt

$14.86B

Free Cash Flow

$5.60B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

42.22

Forward P/E

21.22

Beta

0.87

52-Week High

$404.87

52-Week Low

$329.16

EPS

$8.41

50-Day Avg

$359.65

200-Day Avg

$374.73

Price/Book

6.06

Technical Analysis

Stryker Corporation (SYK) has shown a bearish trend over the past 52 weeks, declining approximately 7.9% from its peak around $400 in February to the current price of $355.03. Key resistance is noted at $358.29, which corresponds with previous highs and recent attempts to break above this level. Support appears to be established just below $350, where the price found a floor in earlier months. Over the last few weeks, price action has been weak, indicating diminishing buying momentum as the stock hovers near support. Currently, at $355.03, SYK is trading close to the lower range of its 52-week performance, suggesting a potential for further downside or sideways movement unless bullish sentiment emerges. The overall technical outlook implies caution among investors, particularly given the lack of strong upward momentum.

Recent News and Developments

Market Update

Here’s a summary of the latest news and developments for Stryker Corporation (SYK) stock in the past week (February 1-7, 2026):

Market Update

### Stryker Reports Strong Q4 2025 Earnings and Optimistic 2026 Outlook

Market Update

Stryker Corporation announced robust financial results for the fourth quarter and full-year 2025, exceeding analyst expectations. The company reported adjusted earnings per share (EPS) of $4.47, surpassing the consensus estimate of $4.40, and revenue of $7.17 billion against an expected $7.12 billion. Following this strong performance, Stryker issued an encouraging outlook for 2026, projecting org

Market Sentiment and Analyst Recommendations

Bull Case

Stryker just crossed $25 billion in annual revenue with 11.4% growth and beat Q4 estimates on both earnings and sales. The 2026 guidance of 8.0-9.5% organic growth puts them at the high end of medtech peers, and that’s conservative relative to recent momentum. Robotics and core products are driving the upside, and a 4.8% dividend increase signals management confidence in cash generation. The consensus price target of $424.39 implies 19.5% upside from current levels, with Needham now targeting $454. At a P/E of 42.22, you’re paying for quality and execution, but Stryker has earned that premium through consistent outperformance. The stock is down 7.9% from February highs despite beating earnings and raising guidance, which looks like institutional accumulation on weakness rather than fundamental deterioration.

Bear Case

A P/E of 42.22 leaves almost no margin for error on growth delivery, especially if macro conditions slow elective procedures. The stock has been weak technically despite good news, closing lower on earnings and dipping 2% on February 3rd while analysts were raising targets, suggesting institutional investors aren’t convinced at current prices. Debt sits at $14.86 billion against $4.10 billion in cash, a net debt position of $10.76 billion that limits financial flexibility if integration or acquisition costs spike. The 2026 guidance midpoint of 8.75% organic growth actually represents a slowdown from 11.4% in 2025, and the market may be pricing in further deceleration. Technical support at $350 is thin, and the stock is already near the lower end of its 52-week range, suggesting downside risk if earnings disappoint or guidance gets cut.

What to Watch

Monitor Q1 2026 results in April for actual execution against the 8.0-9.5% organic growth guidance, particularly robotics segment performance since that’s the stated growth engine. Watch for any commentary on procedure volumes and pricing power in the earnings call, as elective surgery trends are the real driver of medtech outperformance. Track the stock’s ability to hold $350 support and reclaim the $358.29 resistance level, a break above $365 would signal technical reversal and validate the analyst targets. Pay attention to any M&A announcements or capital deployment commentary, as the company has room to deploy that $4.10 billion in cash. Watch medtech sector rotation and Fed policy signals in Q1, as rising rates or recession fears hit discretionary procedures harder than core hospital spending. If the company hits the high end of 2026 guidance and robotics growth accelerates, the path to $424+ becomes credible. If procedure volumes soften or guidance gets cut, the stock could test $330-340 support.

Analyst Consensus

BUY

Based on 28 analyst opinions

Low Target

$316.00

Mean Target

$424.39

High Target

$469.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Devices

Employees

N/A

Earnings & Dividends

Next Earnings

Apr 30, 2026

EPS (Trailing)

$8.41

Dividend Yield

97.0%

Payout Ratio

40.5%

Frequently Asked Questions

Is SYK a good stock to buy?

Analysts recommend SYK as a “BUY,” with a target price of $424.39. The stock currently trades at $355.03, implying a potential upside of around 19.5%. This makes it a compelling opportunity for investors.

What is SYK’s price target?

The analyst consensus price target for Stryker Corporation (SYK) is $424.39. Given its current price of $355.03, this suggests significant growth potential ahead.

Does SYK pay a dividend?

Yes, Stryker Corporation has an impressive dividend yield of 97.0%. This high yield reflects its commitment to returning value to shareholders, making it an attractive option for income-focused investors.

How does SYK’s valuation compare?

SYK’s current P/E ratio is 42.22, which is higher than the industry average, indicating that investors are paying a premium for its growth potential. However, its forward P/E drops to 21.22, suggesting that future earnings may justify the current valuation.

What has been SYK’s stock performance in the last year?

Over the past year, SYK’s stock has fluctuated between $329.16 and $404.87. This range highlights volatility, with the stock currently positioned closer to its lower bound, which may attract bargain hunters.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.